NCT03674541View on ClinicalTrials.gov

The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 14, 2020

Primary Completion Date

December 5, 2021

Study Completion Date

December 20, 2021

Conditions
Myalgic Encephalomyelitis/Chronic Fatigue SyndromeChronic Fatigue SyndromeMyalgic EncephalomyelitisExercise IntoleranceDysautonomiaLow Ventricular Filling Pressures (Preload Failure)Postural Orthostatic Tachycardia SyndromeOrthostatic HypotensionFibromyalgia
Interventions
DRUG

Pyridostigmine Bromide

Pyridostigmine Bromide 60 mg capsule by mouth as a one time dose

DRUG

Placebo

Placebo (Cellulose microcrystalline) capsule by mouth as a one time dose

Trial Locations (1)

02215

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT03674541 - The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome | Biotech Hunter | Biotech Hunter